John R Fischer

Frazier Healthcare promotes Ryan Lucero and Christina Reszka to general partner

Frazier has invested in over 200 companies and raised over $11 billion of capital for private funds and co-investment opportunities.

Windrose Health Investors launches technology services team

WindRose is a New York-based PE firm with approximately $7 billion AUM and invests in healthcare services.

PE bets on caregiver services: 6 deals

Carlyle, HIG Capital, LLR Partners and Main Capital are among the PE firms transacting in caregiver services.

‘$1 trillion gap’ attracts private equity to women’s health, says Kearney’s Paula Bellostas Muguerza; Astorg, Cinven, Nordic target pathology assets

Speaking with Kearney’s Paula Bellostas Muguerza about trends driving PE dealmakers to the women's health sector; a look at deals in the pathology sector and the tailwinds behind them; discussing the $1.1 billion sale of EyeSouth Partners to Cencora and the growth of the business under Olympus Partners.

PE targets pathology assets: 5 deals

Astorg, Cinven, Nordic Capital, Consonance and Pike Street are among the firms pursuing transactions in pathology.

Women's health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza

Blackstone and TPG's $18.3bn take-private of Hologic, which is expected to close soon, is a bellwether.

InTandem, NMS, WestView drawn to healthcare benefits management; B-Flexion Life Sciences closes specialty pharmaceutical merger

Firms such as InTandem, NMS Capital and WestView Capital seize investment opportunities in the healthcare benefits management services segment; Palladium Equity Partners agrees to acquire a hospice care equipment provider from WayPoint Capital Partners; looking at a completed merger between two specialty drug makers under B-Flexion Life Sciences.

PE targets healthcare benefit management: 5 deals

InTandem, NMS Capital and WestView Capital are among the PE firms investing in employer and employee healthcare benefit services.

Ardian, CVC, Verdane eye investments in women’s health; Momentum in pathology services drives exit by Exellere, GHO

Highlighting how various subsegments of the women’s health market have caught the eye of private equity firms such as Ardian, CVC and Verdane; a look at Excellere Partners and GHO Capital Partners’ $950 million agreement to sell a pathology services company to Agilent Therapeutics; new appointments announced by Vistria.

Vistria names David Schuppan, Phil Alphonse as co-heads of flagship funds

The appointments will support the firm's operating structure with its evolving scale and strategic priorities as part of its future growth.